DNER and prostate cancer: EP31670 (NEO2734) is a novel potent oral dual BET and p300/CBP inhibitor, which shows more efficient tumor-killing ability than non-dual BET inhibitors in numerous solid tumors.335 This compound has also entered into the phase I clinical trial in the treatment of castrate-resistant prostate cancer and NUT carcinoma (Table 2).